Trial Profile
Phase II study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 28 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 28 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.